Boutique CRO Redoxis is a small preclinical CRO focused on inflammation and autoimmune conditions with capabilities in in vivo, ex vivo, and in vitro efficacy and MoA studies, offering a potential partner for early product development and translational research.

Grants & Funding Recent grant activity and European funding (ALPHAVAC project with AlpNova/Amarna) indicate strong interest in collaborative R&D and potential co-funded projects, suggesting opportunities for joint grant-supported feasibility or screening platform studies.

Screening Platform Development of AlphaSelect Alphavirus-based screening platform positions Redoxis as a capability for target validation and mechanism-of-action studies, which could complement partner programs seeking efficient early-stage screening.

Low Revenue, High Potential Current reported revenue is below one million with a lean team, implying agility and cost-effective engagement for sponsors while offering scalable services for growing biotech clients in inflammation and autoimmune spaces.

Strategic Fit Industry peers in immunology-focused CROs with mid-sized teams show market adjacency; Redoxis could target biotech startups and small to mid-size pharma with early efficacy and PK/ADME services, offering a partnership route for trial-ready programs.